- cafead   Jul 19, 2024 at 11:52: AM
via Teva Pharmaceutical has reported positive data from the Phase III SPACE clinical trial of AJOVY (fremanezumab) in preventing episodic migraines in children and adolescent patients aged six to 17 years.
article source
article source